Note: All changes are versus the prior-year period unless otherwise stated
"The third quarter was another quarter of strong profitable growth for Merck with all three business sectors and all regions contributing," remarked Merck KGaA chief executive Belén Garijo.
As detailed earlier this month, Merck now expects sales this year of between €19.3 billion ($22.1 billion) and €19.85 billion ($22.8 billion), lifted from an earlier range of €18.8 billion ($21.6 billion) to €19.7 billion ($22.6 billion), mainly due to "a very strong operating performance" in its Life Sciences business. Meanwhile, earnings per share are forecast to be between €8.50 ($9.75) and €9.00 ($10.32), boosted from a prior range of €7.80 ($8.95) to €8.50 ($9.75).
To read more Top Story articles, click here.